A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

Clinical trial NCT03605836 · COMPLETED

Trial details

NCT number: NCT03605836
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Attention Deficit Disorder Attention Deficit Hyperactivity Disorder

Start date: 2019-01-16
Primary completion: 2020-05-14
Enrollment: 590

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.